Tullis Growth Fund Ii, L.p. - Net Worth and Insider Trading

Tullis Growth Fund Ii, L.p. Net Worth

The estimated net worth of Tullis Growth Fund Ii, L.p. is at least $6 Million dollars as of 2024-11-29. Tullis Growth Fund Ii, L.p. is the 10% Owner of Exagen Inc and owns about 1,543,155 shares of Exagen Inc (XGN) stock worth over $6 Million. Details can be seen in Tullis Growth Fund Ii, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Tullis Growth Fund Ii, L.p. has not made any transactions after 2023-06-15 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Tullis Growth Fund Ii, L.p.

To

Tullis Growth Fund Ii, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Tullis Growth Fund Ii, L.p. owns 1 companies in total, including Exagen Inc (XGN) .

Click here to see the complete history of Tullis Growth Fund Ii, L.p.’s form 4 insider trades.

Insider Ownership Summary of Tullis Growth Fund Ii, L.p.

Ticker Comapny Transaction Date Type of Owner
XGN Exagen Inc 2023-06-15 10 percent owner

Tullis Growth Fund Ii, L.p. Latest Holdings Summary

Tullis Growth Fund Ii, L.p. currently owns a total of 1 stock. Tullis Growth Fund Ii, L.p. owns 1,543,155 shares of Exagen Inc (XGN) as of June 15, 2023, with a value of $6 Million.

Latest Holdings of Tullis Growth Fund Ii, L.p.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
XGN Exagen Inc 2023-06-15 1,543,155 3.84 5,925,715

Holding Weightings of Tullis Growth Fund Ii, L.p.


Tullis Growth Fund Ii, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Tullis Growth Fund Ii, L.p. has made a total of 1 transactions in Exagen Inc (XGN) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Exagen Inc is the acquisition of 167 shares on June 15, 2023, which cost Tullis Growth Fund Ii, L.p. around $519.

Insider Trading History of Tullis Growth Fund Ii, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Tullis Growth Fund Ii, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Tullis Growth Fund Ii, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Tullis Growth Fund Ii, L.p. is -24.53%. GuruFocus also compares Tullis Growth Fund Ii, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Tullis Growth Fund Ii, L.p. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Tullis Growth Fund Ii, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Tullis Growth Fund Ii, L.p.

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -16.15 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -17.95 LIMIT LIMIT LIMIT LIMIT LIMIT

Tullis Growth Fund Ii, L.p. Ownership Network

Ownership Network List of Tullis Growth Fund Ii, L.p.

No Data

Ownership Network Relation of Tullis Growth Fund Ii, L.p.

Insider Network Chart

Tullis Growth Fund Ii, L.p. Owned Company Details

What does Exagen Inc do?

Who are the key executives at Exagen Inc?

Tullis Growth Fund Ii, L.p. is the 10 percent owner of Exagen Inc. Other key executives at Exagen Inc include 10 percent owner Nmsic Co-investment Fund, L.p. , director & President and CEO John Aballi , and Chief Financial Officer Kamal Adawi .

Exagen Inc (XGN) Insider Trades Summary

Over the past 18 months, Tullis Growth Fund Ii, L.p. made 1 insider transaction in Exagen Inc (XGN) with a net purchase of 167. Other recent insider transactions involving Exagen Inc (XGN) include a net purchase of 30,887 shares made by John Aballi , a net sale of 19,522 shares made by Kamal Adawi , and a net sale of 200,000 shares made by Nmsic Co-investment Fund, L.p. .

In summary, during the past 3 months, insiders sold 200,000 shares of Exagen Inc (XGN) in total and bought 46,603 shares, with a net sale of 153,397 shares. During the past 18 months, 253,341 shares of Exagen Inc (XGN) were sold and 87,171 shares were bought by its insiders, resulting in a net sale of 166,170 shares.

Exagen Inc (XGN)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Exagen Inc Insider Transactions

No Available Data

Tullis Growth Fund Ii, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Tullis Growth Fund Ii, L.p.. You might contact Tullis Growth Fund Ii, L.p. via mailing address: 11770 Us Hwy 1, Ste 503, Palm Beach Gardens Fl 33408.

Discussions on Tullis Growth Fund Ii, L.p.

No discussions yet.